Réka Ágnes Haraszti

This study shows that cryopreservation of siRNA-treated cells maintains silencing efficacy, with optimal siRNA exposure duration and temperature.

This study examines how chemical modifications affect the duration of RNAi-based therapies in rapidly dividing cells, finding that specific modifications can extend silencing duration significantly.

This study identifies a miR-374b mimic that selectively inhibits GVHD while enhancing GvL, demonstrating the potential of chemically modified miRNA therapies to improve T-cell-based cancer treatments.

This study systematically compares siRNA delivery methods to T cells, finding lipid-conjugate-mediated delivery is most effective for both resting and activated T cells ex vivo.